Despite major therapeutic advances, breast cancer remains prone to recurrence, particularly in patients with early-stage ...

Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future BLA FilingNew Data from MRD Study Reinforces IMNN-001's Promise ...

This work was supported by the National Natural Science Foundation of China (Grant No. 82373113, XJ), Shenyang Breast Cancer ...

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...

For patients with chronic lymphocytic leukemia (CLL), minimal residual disease (MRD) has emerged as a highly sensitive indicator of disease burden during and at the end of treatment, and has ...

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced the initiation of a new ...

Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, at the University of Washington, determines the optimal use of minimal residual disease (MRD) in individual ...

MILAN — The landscape of hematologic malignancies is shifting rapidly, in part due to the evolving significance of measurable (formerly "minimal") residual disease (MRD). Once confined to the realm of ...

An update from Mount Ridley Mines Limited ( ($AU:MRD) ) is now available. Mount Ridley Mines Limited has issued 1,040,766 new shares in its ...